Female Reproductive System Adenocarcinoma

Female Reproductive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

454 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 158
Recruiting: 74
Ph III recruiting: 10
Growth YoY: +19%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (59)

clinicaltrialsPublishedShowing 51–75 of 75 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00309959	ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer	completed	Phase 2	37	Gynecologic Oncology GroupNETWORK	1	Jan 8, 2019	clinicaltrials
NCT00369122	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer	completed	Phase 2	60	National Cancer Institute (NCI)NIH	2	Mar 20, 2018	clinicaltrials